Janssen and Bayer will close their South Korean facilities

| By | Bayer, Drug Manufacturing, Janssen

Janssen and Bayer will join global pharmaceutical companies that have pulled their manufacturing facilities out of Korea over rising payroll costs and intensifying conflicts with unions.

The two international drug makers will close their pharmaceutical factories here soon, according to their local subsidiaries.

Janssen Korea will close its Hyangnam plant in Hwaseong, Gyeonggi Province, by the end of 2021. The company in charge of Johnson & Johnson’s pharmaceutical business in Korea set up the factory in 1983. Industry officials expect domestic drug makers will acquire the plant within the next year.

Janssen Korea said the move was in line with global headquarters’ policy of enhancing efficiency.

Bayer will close its contrast agent manufacturing facility in Anseong, Gyeonggi Province, by the end of this year and move it to Germany, where the pharmaceutical company’s head office is located. Bayer Korea notified employees of the plan in May last year. The company cited the shrinking domestic market as a reason for the shutdown.

Including the Bayer and Janssen factories, 16 factories of global drug makers have closed over the past 20 years. Most of the companies moved their plants to China and Southeast Asian countries. Industry officials fear that local units of global pharmaceutical companies may become importers, not manufacturers.

Johnson & Johnson, Janssen Vaccines and Korea Otsuka Pharmaceutical are the only three global pharmaceutical firms that have yet to decide whether to close their manufacturing facilities here. Johnson & Johnson specializes in quasi-drugs.

Janssen and Bayer vowed to continue their Korean operations, making investments in the Korean market even after closing their factories here.

SOURCE: korea times
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.